PATENT CLAIM ANALYSIS

Application Number: 15742484
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-07
Patent Classification: ["435", "007920"]

Abstract:
The invention relates to a method for assessing the prognosis of idiopathic membranous nephropathy in a subject, based on the analysis of PLA2R1 epitope profile. The invention further relates to a method for monitoring the progression of idiopathic membranous nephropathy based on the analysis of the PLA2R1 epitope spreading. The invention highlights that three PLA2R1 domains (Cys R, CTLD1 and CTLD7) are involved in anti-PLA2R1 activity, with two of them (CTLD1 and CTLD7) more closely associated with active idiopathic membranous nephropathy and likely linked by a mechanism of epitope spreading.

Claim (Index 14):
A method for monitoring the effectiveness of a treatment of membranous nephropathy or idiopathic membranous nephropathy in a subject, comprising:\n determining at a first time point a first level of at least one, two, or three autoantibodies selected from the group consisting of an autoantibody directed against CysR of PLA2R1, are autoantibody directed against CTLD1 of PLA2R1, and an autoantibody directed against CTLD7 of PLA2R1, in a biological sample obtained from said subject at said first time point, determining at a second time point a second level of said at least one, two, or three autoantibodies selected from the group consisting of an autoantibody directed against CysR of PLA2R1, ara autoantibody directed against CTLD1 of PLA2R1, and an autoantibody directed against CTLD7 of PLA2R1, in a biological sample obtained from said subject at said second time point, and comparing the first and second levels of autoantibodies, wherein either or both of:\n absence, from the biological sample obtained from the subject at the second time point, of detectable autoantibodies respectively directed against CTLD1 and CTLD7, or a decrease of the second level of autoantibodies respectively directed against either or both of CTLD1 and CTLD7 relative to the first level, indicates that the treatment is effective; and \n presence, in the biological sample obtained from the subject at the second time point, of detectable autoantibodies directed against either or both of CTLD1 and CTLD7, or an increase in the second level of autoantibodies directed against either or both of CTLD1 and CTLD7 relative to the first level, indicates that the treatment is not effective.

Metadata:
- Claim Count in Document: 32.0
- Percentile: 86.0
- Lexical Diversity: 1.85185
- Patent Class: 435.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['15328563', '13006864', '13641610', '14001827', '15526851']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.5351115960895887
- 35 USC 102 Novelty (BERT): 0.5464326981899
- Combined Prediction Score: 0.5362437062996198
- Mean Citation Score: 258.04373
- Max Citation Score: 395.81674
- Similarity Product: 305.9145787944531

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test